Celldex Therapeutics, Inc. — Director's Dealing 2022

Aug 19, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2022-08-17

Reporting Person: Young Diane C. (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-08-17	Common Stock	M	19000	$10.38	Acquired	21115	Direct
2022-08-17	Common Stock	S	19000	$37.3008	Disposed	2115	Direct
2022-08-17	Common Stock	M	45000	$2.71	Acquired	47115	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-08-17	Incentive Stock Option	$10.38	M	19000	Disposed	2030-06-18	Common Stock (19000)	Direct
2022-08-17	Incentive Stock Option	$2.71	M	45000	Disposed	2029-07-08	Common Stock (45000)	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.30 to $37.35 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F2: 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

F3: 25% vested on July 8, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.